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Abstract. Neuroimaging studies of familial Alzheimer’s disease allow investigation of the disease process before clinical onset.
We performed semi-automated MRI analysis to evaluate cortical thickness (CTh), grey matter (GM) volumes, and GM diffusivity
indexes in PSEN1 mutation carriers (MC). We recruited 11 MC from 4 families with PSEN1 mutations (L286P, M139T, K239N)
and 6 familial and 12 non-familial healthy controls. MC were classified as either asymptomatic (n = 6) or symptomatic (n =
5). Subjects underwent structural and diffusion-weighted 3-Tesla MRI scanning. CTh and GM volumes of subcortical structures
and diffusivity indexes were calculated and group comparisons were performed. Structural images were reanalyzed with voxel-
based morphometry methodology. Cerebrospinal fluid amyloid-β1−42 levels (Aβ) were measured. We found that symptomatic
MC presented widespread cortical thinning, especially in precuneus and parietotemporal areas (p < 0.01) and increased mean
diffusivity (MD) in these areas compared to controls. Unexpectedly, asymptomatic MC, 9.9 years prior to the predicted age
of disease onset, presented increased CTh in the precuneus and parietotemporal areas (p < 0.01), increased caudate volumes
(p < 0.01), and decreased MD (p < 0.05) in these areas compared to HC. In MC, CTh correlated with adjusted age. Aβ
values were within normal limits in AMC. In conclusion, at early preclinical stages, CTh in the precuneus and parietotemporal
regions and caudate volume increase in PSEN1 MC and decrease thereafter with disease progression. The different trends in
MD in asymptomatic and symptomatic MC suggest that different microstructural changes underlie the contrasting morphometric
findings. Reactive neuronal hypertrophy or/and inflammation may account for increased CTh and decreased MD in asymptomatic
MC.
Keywords: Alzheimer disease, amyloid, cerebrospinal fluid, magnetic resonance imaging, presenilin 1
INTRODUCTION
Most Alzheimer’s disease (AD) cases are spo-
radic, typically occurring in persons over 65 years of
age. However, a minority of AD cases are inherit-
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ed with an autosomal dominant pattern. Genetic de-
fects in three genes have so far been described in
these inherited forms: the amyloid-β protein precursor
(AβPP), the presenilin-1 (PSEN1), and the presenilin-2
(PSEN2) [1]. These forms have an early age of on-
set, which is relatively predictable, with nearly 100%
penetrance. These forms constitute, therefore, an ide-
al scenario with few confounding factors to study the
preclinical stage of the disease.
Functional neuroimaging has revealed functional al-
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terations in the target brain AD areas as long as 30
years prior to the mean familial age of disease onset [2],
and MR spectra have shown metabolite abnormalities
a decade before the expected onset [3]. Structural
changes such as medial temporal or global brain atro-
phy [4], or accelerated rate of grey matter (GM) loss [5],
have also been found in mutation carriers (MC) years
before clinical onset, although brain atrophy seems to
occur later than functional abnormalities [6].
Recently, new methods have been developed for the
measurement of cortical thickness (CTh) across the en-
tire mantle that have proven their usefulness in detect-
ing widespread abnormalities in early phases of spo-
radic AD [7], even in asymptomatic subjects in whom
positive amyloid binding suggests cortical amyloid de-
position [8]. This technique has proved useful in as-
sessing subtle structural longitudinal changes in AβPP
and PSEN1 MC, finding a decrease in CTh in the pos-
terior cingulate and in the precuneus prior to symptom
onset [9].
Diffusion tensor imaging (DTI) is a technique that
allows investigation of brain microstructure integrity
based on the directionality of the diffusion of water
molecules. Mean diffusivity (MD) provides a scalar
measure of total diffusivity. Although it has been more
widely studied in white matter, MD can also be used in
the study of the integrity of grey matter in AD and mild
cognitive impairment patients [10]. In this sense, in a
recent study in healthy elderly, changes in MD predict-
ed memory performance, whereas volume changes did
not [11].
The aim of the present study was to analyze the
CTh and subcortical GM structure volumes and GM




Eleven mutation carriers from 4 families with 3 dif-
ferent PSEN1 mutations (M139T, L286P, K239N) were
recruited from the genetic counseling program for fa-
milial dementias (PICOGEN) at the Hospital Clinic,
Barcelona, Spain. These mutations have been pub-
lished elsewhere [1,12,13]. All the subjects approached
already knew their at-risk status for genetic AD. At-
risk subjects received a session of genetic counseling
and were given the option of knowing their genetic
status through the genetic counseling protocol. Six at
risk individuals who were found to be non carriers and
twelve healthy volunteers, age- and gender-matched to
the asymptomatic MC (AMC), were also recruited to
increase the statistical power of the sample. The study
was approved by the local ethics committee and all
subjects gave informed written consent.
Clinical and neuropsychological characterization
Subjects underwent clinical and cognitive evalua-
tions. The comprehensive neuropsychological battery
included verbal and visual memory (Free and Cued
Selective Reminding Test-FCSRT and Rey-Osterrieth
Complex Figure), semantic memory (animals fluency),
language (Boston Naming Test and language compre-
hension of the Boston diagnostic Aphasia Battery-),
praxis (ideomotor praxis and constructive praxis from
the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD), visual perception (incomplete let-
ters and number location subtest from Visual Object
and Space Perception Battery-VOSP) and frontal func-
tion (Controlled Oral Word Association Test- COWAT,
Trail Making Test part A and B, digit span) assessment
was used. The Pfeffer Functional Activities Question-
naire (FAQ) was used for assessing patients’ functional
activities. Subjects were classified clinically as asymp-
tomatic if they had no memory complaints, a normal
cognitive evaluation and the Clinical Dementia Rating
(CDR) scale performed with an informant was 0; or
symptomatic if cognitive performance was more than
1.5 SD below the mean respect their age and education
level in any cognitive test or CDR > 0. Symptomat-
ic MC (SMC) were further classified as non-demented
(SMC-ND) if CDR = 0.5 or demented (SMC-D) if
CDR > 1.
This study included four families with three different
mutations, with different median ages of onset (46, 40,
and 52.5 years respectively). Because PSEN1 MC have
an early age of onset with nearly 100% penetrance and a
relatively predictable age of onset within a given family
we defined and calculated for each MC the adjusted age
as the subject’s age relative to the median familial age
of onset.
Genetic analysis
Genomic DNA was extracted from peripheral blood
of probands using the QIAamp DNA blood minikit (Qi-
agen). Mutation screening was performed as previous-
ly described [12].
Apolipoprotein E (APOE) genotyping was per-
formed by polymerase chain reaction amplification and
HhaI restriction enzyme digestion.
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CSF analysis
CSF study was offered to at-risk individuals. CSF
was obtained and processed according to standard pro-
tocols. CSF Aβ1−42 concentrations were determined
by ELISA, provided by Innogenetics , Gent, Belgium
(Innotest β-amyloid 1-42).
MRI acquisition
Subjects were examined on a 3T MRI scanner (Mag-
netom Trio Tim, Siemens Medical Systems, Germany).
A high resolution 3D structural dataset (T1-weighted
MP-RAGE, TR = 2300 ms, TE = 2.98 ms, 240 slices,
FOV = 256 mm; matrix size = 256× 256; Slice thick-
ness = 1 mm) was acquired for the 29 subjects in-
cluded. The DWI protocol consisted of an echo-planar
imaging (EPI) sequence (30 directions+b0 image, with
2 repeated acquisitions, TR = 7600 ms, TE = 89 ms,
60 slices, slice thickness = 2 mm, distance factor =
0%, FOV = 250 mm, matrix size = 122 × 122, voxel
size = 2 × 2 × 2 mm).
Cortical thickness and volumetric segmentation
procedures
Cortical reconstruction and volumetric segmenta-
tion of the structural images was performed with
the FreeSurfer image analysis suite, version 4.3.1
(http://surfer.nmr.mgh.harvard.edu). The procedures
have been fully described elsewhere [14]. In short, re-
constructed and registered individual CTh maps were
smoothed using a Gaussian kernel of 20 mm Full-Width
Half Maximum and introduced in a group analysis,
based on general linear modeling (GLM) of the data
(age, gender, and family were introduced as covariates).
Regions that presented significant differences between
groups were used to define regions of interest (ROI)
for analysis in further region-specific studies. We al-
so manually drew another ROI in the primary visual
cortex to serve as a control structure (VisualROI) [8].
Furthermore, within the FreeSurfer streamline, a par-
cellation of each individual surface was performed with
two different atlases available [15,16]. Mean thick-
ness of the parcellations of interest were used to do
between-groups comparisons, and regression analysis
with adjusted age.
Subcortical segmentation was performed also as im-
plemented in FreeSurfer. The segmentation procedure
allows the obtainment of a measure of the estimated
Intracranial Volume (EIV) [17], which is based on the
scale factor used for the atlas registration. Finally, GM
volumes for all the subcortical segmented structures
were extracted for each subject.
CTh analyses were done with and without a correc-
tion for multiple comparisons. The uncorrected results
were thresholded at p < 0.01 level. We performed
two different kinds of multiples comparison correction.
First a FDR multiple comparison correction was ap-
plied. Moreover a Familywise Error (FWE) permuta-
tion testing (500 permutations) was performed, as im-
plemented in FreeSurfer.
Voxel based morphometry (VBM) analysis
Structural MRI data were also processed with FSL-
VBM stream protocol, a voxel-based morphometry
style analysis included in the FSL suite (http://www.
fmrib.ox.ac.uk/fsl) [18]. Procedures within this proto-
col allow an accurate voxelwise comparison of indi-
vidual grey matter maps, using GLM (age, gender, and
family were introduced as covariates) and permutation-
based non-parametric testing and correcting for multi-
ple comparisons across space, using family-wise error
(FWE) correction.
Analysis of diffusion MRI data
Diffusion MRI was processed using tools imple-
mented in FSL. First, individual MD maps were ex-
tracted for each subject. These maps were registered
to MNI152 space and introduced into a GLM analysis
to perform group comparisons. Appropriate registra-
tion tools were applied to extract mean MD values in
the different ROIs. MD analyses using a cortical mask
are presented corrected for multiple comparisons, us-
ing FWE algorithm, and thresholded at p < 0.05 level
of significance.
Statistical analysis
Group analyses were made using the Statistical Pack-
age for Social Sciences (SPSS) v.16 (Chicago,Il, USA).
Comparisons between groups (SMC/AMC versus HC)
were performed using two-tailed t-tests
RESULTS
Demographic and clinical characteristics and genetic
status
Demographic data and APOE genotype of all partic-
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Table 1
Demographic data of the participants
Subject Family Gender Age Relative CDR sum MMSE APOE
(years) age (years) of boxes
SMC group SMC1 1 Female 38 −1.99 2 28 33
SMC2 1 Female 45 5.36 5,5 24 33
SMC3 1 Male 43 3.15 2,5 24 33
SMC4 2 Male 51 4.98 10 17 43
SMC5 3 Female 60 7.27 14 11 33
AMC group AMC1 2 Male 33 −12.79 0 30 33
AMC2 2 Female 32 −14 0 30 23
AMC3 3 Female 45 −7.4 0 29 33
AMC4 3 Female 49 −3.58 0 27 33
AMC5 3 Female 55 2.97 0 29 33
AMC6 4 Male 33 −12.3 0 28 33
HC group HC1 1 Female 44 − 0 29 43
HC2 1 Female 35 − 0 30 33
HC3 1 Female 39 − 0 29 33
HC4 3 Female 52 − 0 29 33
HC5 4 Female 25 − 0 29 33
HC6 4 Male 35 − 0 29 33
Non-familiar Male 4/ 42.08 − 0 29.44
HC group Female 8 ± 11.59 ± 0.511
N = 12
ipants is summarized in Table 1. Five MC were SMC
(2 SMC-ND and 3 SMC-D) with a median age of 45
years (range 38–60 years), median adjusted age of 5.0
years (range−1.9–7.3 years). Six MC were AMC with
a median age of 39 years (range 32–55 years) and me-
dian adjusted age of −9.9 (range −14.0 to 3.0 years),
and 18 participants were HC (median age 39.4 years;
range 25.2 to 59.8 years). Age, education, gender, and
MMSE did not differ between HC and AMC. As ex-
pected, SMC were older than HC and AMC and pre-
sented significant differences on all clinical and func-
tional scales.
Four SMC and 3 AMC consented to participate in
the study of CSF Aβ levels. The 4 SMC presented
abnormally low values (mean 175 pg/mL), while AMC
presented normal values (mean 776 pg/mL).
Structural analysis
The estimated intracranial volume (EIV) did not
differ between HC and AMC (1475790 mm3 versus
1488259 mm3, p = 0.87) or between HC and SMC
(1463620 mm3, p = 0.89). EIV was therefore not
included in subsequent statistical models.
Cortical thickness analysis in symptomatic and
asymptomatic mutation carriers
Analysis of whole brain CTh maps revealed signifi-
cant thinning (p < 0.01 uncorrected) in SMC in many
areas across the entire cortical mantle (SympROI). A
separate analysis between HC and both SMC-ND and
SMC-D was performed (Fig. 1). The difference maps
between HC and each subgroup showed that although
the pattern of thinning in the SMC-ND was similar to
that of SMC-D, its extension and magnitude was clear-
ly lower than in SMC-D. The posterior cingulate and
precuneus (PPC) and posterior association areas – the
superior temporal gyrus (ST), the banks of the superi-
or temporal sulcus (BSTS), inferior and superior pari-
etal cortex (IP and SP), fusiform gyrus (FG) – present-
ed more severe and widespread cortical thinning than
frontal areas where the thinning appeared more restrict-
ed to certain specific regions (anterior cingulate, pars
triangularis, pars orbitalis, frontal pole, orbitofrontal,
and superior frontal). There were minor differences in
the spatial location of regional thinning across hemi-
spheres, but the results were quite consistent bilateral-
ly. We also found a region of focal cortical thickening
in the anterior right cingulate cortex present in both
SMC-ND and SMC-D patients when compared to HC.
Figure 2 shows the difference maps for the AMC
group in comparison with the HC group. Only small
scattered areas of cortical thinning across the cortex
appeared. Unexpectedly, several regions – the PPC,
the BSTS, the IP, the SP and the FG – showed cortical
thickening. Some of these regions (precuneus, BSTS,
supramarginalis and IP areas) survived the FWE multi-
ple comparison correction which are shown in Table 2
and a region in the PPC also survived FDR correction
(shown in Fig. 3). Uncorrected differences are repre-
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Fig. 1. Cortical thickness (CTh) difference maps in different clinical stages: (A) Non-demented symptomatic mutation carriers, (B) Demented
symptomatic mutation carriers. Both compared against the healthy control group (p < 0.01 uncorrected). Red-yellow color code means decreased
CTh, and blue color code means increased CTh.
Fig. 2. Cortical thickness (CTh) difference maps for the contrast AMC versus HC. Thresholded at p < 0.01, uncorrected. Red-yellow color code
means decreased CTh, and blue color code means increased CTh.
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Table 2
Familywise Error (FWE) multiple comparisons correction (500 permutations). Cortical areas corresponding to
each cluster were assigned using the parcellations from an available atlas [15] BTSS = banks of the temporal
superior sulcus
Cluster Size Max p Max-p Tailarach Cluster-Wise Cluster-Wise Atlas label
number (mm2) value coordinates probability confidence
interval
1 613.75 10(−5.2) (−14.3, −46.1, 30.5) 0.05 [0.038–0.062] precuneus
2 766.89 10(−3.6) (−49.4, −41.8, 1.3) 0.01 [0.004–0.016] BTSS
3 876.53 10(−3.6) (−53.1, −35.8, 29.7) 0.002 [0.000–0.004] supramarginal
4 1102.14 10(−3.2) (−29.0, −80.5, 15.3) 0.002 [0.000–0.004] inferiorparietal
Table 3
Average Cortical Thickness (CTh) and group comparisons within the defined regions of interest.
AsympROI refers to areas with increased CTh in the AMC group, SympROI refers to areas
with reduced CTh in the SMC group, and VisualROI serves as a control region
Average CTh (mm) SympROI AsympROI VisualROI
Mean (SD) Mean (SD) Mean (SD)
HC 2.55 (0.09) 2.38 (0.08) 1.62 (0.15)
AMC 2.66 (0.09) 2.64 (0.18) 1.57 (0.11)
SMC Non-demented 2.31 (0.05) 2.26 (0.09) 1.46 (0.12)
Demented 2.04 (0.07) 1.93 (0.06) 1.37 (0.08)
Group Comparisons
HC vs AMC t = 2.5, p = 0.019 t = 5.06, p < 0.001 t = 0.69, p = 0.5
HC vs SMC-ND t = 3.49, p = 0.003 t = 2.04, p = 0.057 t = 1.38, p = 0.18
HC vs SMC-D t = 9.06, p < 0.001 t = 9.63, p < 0.001 t = 2.6, p = 0.015
Fig. 3. Cortical thickness (CTh) difference maps for the contrast AMC versus HC. FDR multiple comparison correction thresholded at p < 0.05.
Blue color code means increased CTh.
sented in Fig. 2 when compared to HC. AsympROI was
created from the map at p<0.01.
Table 3 shows the mean CTh values for each group
in the 3 ROIs (SympROI, AsympROI and VisualROI).
SMC-D presented a 20% decrease in SympROI and
18.9% in AsympROI compared to HC (p < 0.001 and
p < 0.01 respectively), more severe than SMC-ND cor-
tical thinning (5.047% in AsympROI and 9.41% in Sym-
pROI). In AMC, mean CTh presented 10.9% and 4.31%
increases in both AsympROI and SympROI areas when
compared to HC (p < 0.001 and p = 0.019 respective-
ly). These changes were not found in the control region
VisualROI, where only SMC-D presented differences
with HC. We found the same type of changes when
determining CTh in several automatically atlas derived
regions (Table 4).
We found an overlap between the SympROI and the
AsympROI, although the extension of cortical thinning
in SMC was greater than that of cortical thickening in
AMC (Fig. 4).
Figure 5 presents individual mean CTh values in
the AsympROI. Most MC values fall outside the range
of HC values, with higher values for individual mean
CTh in AMC and lower values in SMC. We used the
individual CTh values extracted from the AsympROI
to examine the relationship between the adjusted age
and CTh. There was no correlation between absolute
age and CTh in HC. However, a strong correlation
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Table 4
Average Cortical Thickness (CTh) and group comparisons within the atlas-based regions of interest [16]. Regions are
represented in Fig. 6
CTR AMC t-test SMC T-test
(CTR vs AMC) (CTR vs SMC)
right S subparietal 2.42(0.16) 2.63(0.14) T = 2.85, p = 0.009 2.09(0.29) t = 3.17, p = 0.005
left S subparietal 2.38(0.11) 2.54 (0.19) T = 2.44, p = 0.023 1.83(0.28) t = 6.71, p = 0.000
left S occipital middle 2.10(0.16) 2.30(0.15) T = 2.51, p = 0.020 1.66(0.20) t = 4.65, p = 0.000
and Lunatus
left S occipital superior 2.15(0.16) 2.32(0.09) T = 2.57, p = 0.018 1.81(0.28) t = 3.37, p = 0.003
and transversalis
left S Cingulate 2.21(0.15) 2.36(0.14) T = 2.1, p = 0.047 1.77(0.22) t = 4.97, p = 0.000
marginalis
Fig. 4. Overlap of AMC versus HC (dark blue-light blue), and SMC versus HC (yellow lines) difference maps.
Fig. 5. Correlation between mean cortical thickness (CTh) values measured in the AsympROI and adjusted age of each mutation carrier
(asymptomatic carriers in circles, symptomatic carriers in triangles). Solid line is the adjusted regression line. Solid and dashed lines represent
mean CTh and its range measured in the same ROI for HC.
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Fig. 6. Correlation between mean cortical thickness (CTh) values measured in several ROI obtained by the automated parcellation of the cortex
available in FreeSurfer [16] and the adjusted age of each mutation carrier (asymptomatic carriers in circles and symptomatic carriers in triangles).
Dashed lines represent the mean CTh measured in the same ROI for HC.
Fig. 7. (A) Volume of the atlas-based subcortical segmentations. Mean values within each group. (B) Volume of the atlas-based segmentation
for ventricles and fluid-based segmentations. Mean values within each group. ∗p < 0.05, ∗∗p < 0.01 (group comparisons versus HC).
between individual CTh values and the adjusted age
was found in MC (r = 0.864, p = 0.006, see Fig. 5).
Only one AMC presented values far from the regression
line. Interestingly, this subject was still asymptomatic
at +3 years from predicted disease onset, a finding that
shows the limitation of adjusted age as prediction of
disease onset. The same type of results are obtained
when analyzing this correlation in ROIs obtained with
an automated parcellation of the cortex) [16] in areas
of interest (Fig. 6).
Subcortical grey matter and ventricular volumes in
symptomatic and asymptomatic mutation carriers
Atrophy in the SMC group, measured as a loss of
grey matter, was significant in bilateral hippocampi,
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Table 5
Average Mean Diffusivity measured in the two defined ROIs (SympROI and AsympROI), in the control ROI (VisualROI), and in
subcortical structures. Caud: Caudate, Acc: Accumbens, Amy: Amygdala, Hipp: Hippocampus, Put: Putamen
MD SympROI AsympROI VisualROI Caud Acc Amy Hipp Put
(10−4 Mean Mean Mean Mean Mean Mean Mean Mean
cm2/s) (SD) (SD) (SD) (SD) (SD) (SD) (SD) (SD)
HC 8.40 (0.55) 8.70 (0.56) 4.09 (0.53) 12.67 (1.76) 8.34 (0.46) 8.73 (0.28) 11.7 (0.63) 7.32 (0.36)
AMC 7.74 (0.28) 8.00 (0.56) 3.79 (0.57) 10.23 (1.46) 8.22 (0.56) 8.64 (0.28) 10.9 (0.36) 7.44 (0.27)
SMC 9.90 (0.43) 10.7 (8.77) 4.58 (0.67) 16.34 (0.80) 9.04 (0.75) 9.69 (1.12) 14.4 (1.53) 7.69 (0.31)
Group comparisons(t-test)
SMC vs HC p < 0.001 p < 0.001 p = 0.11 p < 0.001 p = 0.02 p = 0.13 p = 0.016 p = 0.054
HC vs AMC p = 0.028 p = 0.014 p = 0.28 p = 0.01 p = 0.64 p = 0.54 p = 0.018 p = 0.512
Fig. 8. VBM results. A) AMC versus HC (p < 0.05, corrected), (B) HC versus SMC (p < 0.05, corrected). Red-yellow color code means
decreased volume, and blue color code means increased volume.
accumbens, putamen, and left caudate and amygdale
with respect to HC. In contrast, AMC presented sig-
nificant enlargement of the caudate bilaterally with re-
spect to HC (p < 0.01 left caudate, p < 0.05 right
caudate). Although without reaching statistical signif-
icance, many of the other atlas-based structures found
to be atrophied in SMC were also enlarged in the AMC
group (Fig. 7A).
Ventricular size showed the opposite trend. SMC
showed a significant increase in ventricular size com-
pared to HC whereas AMC showed significantly low-
er volumes. Moreover, these changes were found in
the supratentorial compartment (lateral and third ven-
tricles) with preservation of the 4th ventricle (Fig. 7B)
Voxel based morphometry analysis
VBM results are shown in Fig. 8. SMC showed sig-
nificant widespread GM atrophy, mostly in PPC, pari-
etotemporal association areas, lateral temporal (p <
0.05, corrected for multiple comparisons) and both cau-
dates and bilateral putamen. AMC showed increased
volume in right caudate. No areas were found enlarged
in the SMC compared to HC or in the HC compared to
the AMC.
Diffusivity indexes: Mean diffusivity in the cortex and
caudate
The general linear model (GLM) analysis restricted
to the cortex corrected for multiple comparisons across
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Fig. 9. A) Regions showing increased mean diffusivity (MD) in cortex in SMC versus HC (B). Regions showing reduced MD in cortex in AMC
versus HC. Maps have been thresholded at p < 0.05, corrected.
space showed an increase in MD across the whole cere-
bral cortex in SMC compared to HC (p < 0.05 correct-
ed). AMC presented changes in the opposite direction,
with a decrease in MD mainly in PPC, cuneus and the
IP (Fig. 9) compared to HC (p < 0.05, corrected).
To determine whether the areas that presented signif-
icant thickening co-localized with those areas with re-
duced diffusivity, MD was calculated in the AsympROI,
SympROI, VisualROI, and several subcortical structures
(Table 5). SMC showed a significant increase in MD in
the AsympROI and SympROI (both p < 0.001) where-
as AMC showed a significant decrease in MD (p =
0.03 and p = 0.004 respectively). The same trend
of changes was also observed in subcortical structures
(Table 5). Thus, in SMC, the caudates, accumbens,
and hippocampi presented significant increases in MD
whereas AMC showed significant decreases in MD in
the caudates and hippocampi compared to HC. Nei-
ther SMC nor AMC showed differences in MD (p =
0.11 and p = 0.28 respectively) in the control area. In
addition, when we fused MD in AMC with the areas
that presented significant thickening in a sole figure
(Fig. 10), the two areas showed a clear visual overlap.
DISCUSSION
We performed a study of structural and diffusivity
indexes in cortical and subcortical grey matter in both
symptomatic and asymptomatic PSEN1 MC. SMC pre-
sented widespread cortical thinning in PPC and pari-
etotemporal association areas in a pattern that resem-
bles the “AD signature” of sporadic AD [7,8]. This
pattern of GM cortical loss was already present at the
non-demented stage, but to a much lesser extent sim-
ilar to previous reports in sporadic AD [19]. Our re-
sults in SMC are consistent with, and expand on, previ-
ous findings in PSEN1 and AβPP SMC. Hippocampal
and global cerebral atrophy in SMC has been identi-
fied with volumetric MRI studies [5,6]. CTh has been
shown to be decreased in several ROIs (entorhinal cor-
tex, parahippocampal gyrus, PPC), but not in control
regions in MC [9], demonstrating an accelerated de-
cline in CTh in all target ROIs. In addition, in our
study, the diffusivity analysis restricted to the GM in
SMC replicated the expected findings [10], that is, an
increase in MD across the whole cerebral cortex, target
regions, and the subcortical structures affected.
In contrast, in AMC we found increased CTh in the
PPC and parietotemporal association areas. This result
was unexpected. For this reason and the fact that it was
derived from the study of a small number of subjects
(which constitutes the main limitation of the study)
we performed several further analyses to support these
findings. First, some areas survive multiple compar-
isons correction despite the small number of subjects
in the sample. Second, the results at the individual lev-
el support the statistical analysis, as most AMC CTh
individual mean values in the AsympROI fall outside
the range of HC CTh. Third, CTh showed a significant
correlation with the adjusted age of disease onset not
only in the AsympROI, but also in several other ROIs
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Fig. 10. Overlap of cortical thickness and mean diffusivity difference maps for AMC subjects. Green lines surround regions of cortical thickening
(p < 0.05), and red-yellow regions are those where MD was found to be decreased in the AMC group. MD maps are mapped from volumetric
to surface-based representation.
automatically extracted from FreeSurfer in the areas
of interest, suggesting that the same areas found to be
thickened suffer from thinning in MC as the disease
progresses. Fourth, investigating the “specificity” of
the areas involved, we found inverse changes in CTh
in SMC and AMC in regions that present substantial
visual overlap (SympROI and AsympROI), but not in the
control region (VisualROI). Finally, the increase in CTh
was accompanied by a significant fall in MD values,
suggesting that not only gross structural changes but
also microstructural abnormalities may be occurring.
To the best of our knowledge, this is the first report
of increased CTh in PSEN1 MC. Previous structural
studies in AMC did not find differences, or suggested a
loss of cortical GM in comparison with HC. There are
two possible explanations for this discrepancy. First,
if the shift from increased CTh towards atrophy is to
happen in the asymptomatic phase of the disease, the
results in each study would be critically dependent on
the closeness to the predicted clinical onset of the AMC
included in the sample. Our AMC are more distant
from the predicted clinical onset (median adjusted age
−9.9 years) than the subjects included in previous se-
ries (approximately−4 years) [6,9]. VBM studies have
estimated that medial temporal atrophy and global atro-
phy begin 3 to 3.5 years before mean familial onset [5,
6] and longitudinal measures can identify differences
in the rate of hippocampal GM loss in MC up to 5.5
years before diagnosis [5]. CTh decreased in posterior
cingulate about 1.8 years and in the precuneus 4.1 years
prior to diagnosis [9]. Second, technical differences
may also account for the differences found, at least in
part. Most previous studies have been performed with
a volume-based registration approach instead of using a
surface-based registration. CTh has been shown more
accurate [14] and is a potentially more reliable marker
than volume, as the cytoarchitectural structure of the
grey matter is less variable [9]. Another advantage of
CTh studies is that they may provide significant infor-
mation even in small groups such as ours [20]. In fact,
in the present study only CTh demonstrated cortical
involvement when applying multiple comparisons cor-
rection and in the uncorrected results CTh demonstrat-
ed much more cortical involvement than VBM (data
not shown).
Subcortical GM structures showed significant differ-
ences in the same direction, with significant increases
in volume in both caudates in AMC, while SMC pre-
sented significant volume loss. The diffusivity analysis
in the caudate in AMC showed significantly reduced
MD. These results should be treated with caution be-
cause of possible CSF artifacts (especially MD results
as the FSL VBM streamline already accounts for them
in the volumetric analysis). Basal ganglia did not use
to be considered among the typical areas affected in ge-
netic AD but this idea changed after the demonstration
of significant Aβ deposition in the striatum with much
lower cortical deposition a decade before symptoma-
tology onset in PSEN1 AMC [21,22].
Several lines of evidence in the literature on mor-
phometric studies in humans, pathological data, and
studies in animal models support a possible increase in
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CTh or subcortical GM volume in very early stages of
AD. In a recent paper, APOE ε4 carriers showed thick-
er cortices than non-carriers, but a steeper age-related
thinning in areas known to be affected in AD precisely
in the life period (48–75 years old) when early mor-
phological changes are beginning to emerge [23]. The
authors interpreted the findings as a result of compen-
sation of the underlying pathological processes. We be-
lieve that those results are very similar to ours and that
the explanation presented there may also be applicable
to our case. Moreover the same group has very recently
replicated their results of cortical thickening in APOE
ε4 carriers and reported that APOE ε4 related thicken-
ing modulates selective attention [24]. In pathological
studies of cognitive normal subjects with changes of
AD, cortical and hippocampal neurons show nuclear
hypertrophy, interpreted as a probable reaction to Aβ,
long before the onset of clinical symptoms [25,26]. The
authors interpreted the results as either a compensato-
ry response to AD pathology that prevents cognitive
decline, or as a part of the pathological process. In
animal models, a similar phenomenon was observed in
transgenic mice, with neural hypertrophy and increased
synaptic contacts reported in AβPP/PS1DeltaE9 ani-
mals [27,28]. Morphometric studies with serial MRI
found an increase in cerebral and intracranial size in
double transgenic mice [29]. The interpretation provid-
ed was that the results were a consequence of Aβ load
and the associated inflammatory response (astrogliosis
and microglial activation). In humans, inflammation
has been reported very early in the course of the disease
and there is evidence of complement activation on amy-
loid plaques in non-demented subjects who do not meet
pathologic criteria for AD [30]. Immunotherapy trial
results in AD also suggested that inflammation and Aβ
load could account for GM thickness or volume, where
the removal of Aβ (or other plaque-related proteins)
and alterations in glial cell density have been suggest-
ed as explanations of the volume loss and ventricular
enlargement found among antibody responders [31].
Both changes in cell volume or number produce an
alteration in the cellular compartment with respect to
the total volume within the cortex which may affect
the diffusion of water measured with MD [32]. In our
study, SMC presented the expected increase in MD in
the cortex and caudate, probably as a reflection of neu-
ronal loss [10]. In contrast, AMC showed a significant
decrease in MD, which may have reflected the increase
in both cell volume and number due to an inflammatory
response. Thus, either reactive neuronal hypertrophy or
inflammatory response to Aβ, or probably both, could
account for the increased CTh or volume and decreased
MD found in AMC in our study.
Notwithstanding the absence of previous reports
of cortical thickening in genetic AD, in Huntington
disease (HD) cortical volume or thickness has been
found significantly increased in far-from-onset preclin-
ical HD [33] and YAC128 mice [34]. Paulsen and col-
leagues [33] underlined the possibility of an abnormal
cortical development to explain the increased cortical
volume. Lerch et al. [34] also suggested the possi-
bility of a compensatory response to striatal degenera-
tion or some type of inflammatory response preceding
cell death in accordance with neuropathologicaldata on
preclinical HD [35], which coincides with the interpre-
tation we give to our findings. Whatever the interpreta-
tion both the findings in HD and our present results ex-
pand the ability of structural neuroimaging from detect-
ing atrophy to actually detecting gray matter increases
at earlier stages of neurodegenerative disorders.
On the other hand, while SMC presented abnormal
Aβ mean values, AMC Aβ values were normal, sug-
gesting that in these subjects Aβ fibrillar deposition
was not severe or extensive enough to produce a re-
duction in CSF Aβ levels [36]. Nevertheless, morpho-
metric and microstructural changes in AMC could be
mediated by the toxic effect of Aβ oligomers or diffuse
plaques previous to Aβ fibrillar deposition. However,
the small number of subjects studied and the lack of
amyloid imaging data to evaluate focal fibrillar Aβ de-
position requires us to be extremely cautious with this
interpretation.
Recently, Jack and colleagues summarized the cur-
rently available evidence on sporadic AD and proposed
a model that related disease stage to AD biomark-
ers [37]. In their model, a preclinical phase of the
disease corresponds to the deposition of fibrillar Aβ
marked by reductions in CSF Aβ and increased amy-
loid PET tracer retention. Neurodegeneration appeared
later marked with functional abnormalities, increased
CSF tau and atrophy in MRI. The finding of increased
CTh and caudate volume with normal values of Aβ
does not fit either of the stages described in Jack’s mod-
el. Although we should bear in mind that the model was
proposed for sporadic AD and the sequence of events
in these two populations may differ, our findings could
in fact fit the model if we place our AMC subjects at
the very beginning of the β-amyloidosis phase or in a
previous one, driven by soluble Aβ. As the designers
of this model acknowledged, features such as the role
of toxic Aβ oligomeric species or diffuse plaques and
the timing of their appearance were not included, as
there are currently no reliable biomarkers for them.
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Our study has several limitations. As mentioned
above the first and most important is the small number
of subjects studied, although in rare genetic popula-
tions this is practically inevitable. Therefore we should
emphasize that it will be essential to replicate our find-
ings in other cohorts to confirm our results. Another
limitation in the interpretation of these results is the
use of adjusted age as theoretical construct to substitute
currently unknown real age of onset. We acknowledge
that the absence of Aβ imaging, which is not currently
available, is another limitation in the interpretation of
the results. As discussed above, the study of CSF Aβ
levels was performed to overcome, at least in part, this
problem [37]. In spite of these limitations, we believe
that our findings are robust and can be interpreted in ac-
cordance with previous data. There is a great research
effort devoted to finding imaging biomarkers of early
pathological changes in AD and the present work may
have important implications in this area. However, the
degree to which they can be extrapolated to sporadic
AD remains unknown.
In conclusion, CTh appears to be increased in the pre-
cuneus and parietotemporal association areas in PSEN1
MC during early preclinical stages of the disease. Sub-
cortical GM structures, especially the caudate nucleus,
are also enlarged. With disease progression, these areas
suffer GM loss and become thinner or atrophied. The
increase in mean CTh and caudate volumes in AMC
is associated with a decrease in MD, whereas atrophy
in SMC is associated with increased MD. The inverse
changes in diffusion indices in SMC and AMC suggest
different microstructure abnormalities underlying the
contrasting morphometric findings. Reactive neuronal
hypertrophy or inflammatory response to Aβ, or both,
may account for the increased CTh and decreased MD
found in AMC whereas decreased CTh and increased
MD in SMC may reflect predominant neuronal loss.
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